📇 Rhumatologue · PARIS CEDEX 14 · (75) · Salarié
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Praticien-chercheur
7 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
INSTITUT MEDICO-CHIRURGICAL MONTSOURIS
42 BD JOURDAN, 75674 PARIS CEDEX 14
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
The Journal of investigative dermatology · 2006
International journal of cancer · 2002
AbstractPrimary melanoma (MM) could be a good model to test an intuitive concept: a cancer that is growing fast in its early phase is likely to have a high aggressiveness. Since MMs are visible tumors, many patients can provide information to indirectly assess the kinetics of their lesion. A prospective study was designed to assess if the kinetics of the visible growth of a primary MM, as described by the patient, could be a noninvasive prognostic marker. The ratio of MM thickness to delay between MM appearance and MM removal was used as a surrogate value for the kinetics of the MM growth. To assess the delay between MM appearance and removal, 362 patients with self‐detected invasive MM fulfilled a detailed questionnaire, which provided 2 types of estimations of this delay and thus 2 melanoma kinetics indexes (MKI and MKI*). After a median follow‐up of 4 years, univariate and multivariate analyses assessed whether relapse‐free survival was linked to MKI or MKI*. MKI was significantly predictive of relapse‐free survival (HR = 1.84 [1.51–2.25]) and relapse at 1 year (RR = 2.93 [1.84–4.69]), independently from Breslow thickness. MKI was retained in multivariate prognostic models, just after thickness and before other usual markers. MKI* was also a significant independent risk marker, although less predictive. In this model, the initial growth kinetics of a cancer reflects its aggressiveness and a high index predicts a short‐term relapse. The “subjective” data obtained from patients about their MM history, although usually neglected, can thus provide a better prognostic marker than many “objective” tests. © 2002 Wiley‐Liss, Inc.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
The Tohoku journal of experimental medicine · 2012 · Clinical Trial
Reyal J, Lebas N, Fourme E, Guihard T, et al.
Oncogene · 2003 · Journal Article
Marionnet C, Lalou C, Mollier K, Chazal M, et al.
International journal of cancer · 2002 · Comparative Study
Grob JJ, Richard MA, Gouvernet J, Avril MF, et al.
Annales de pathologie · 2002 · English Abstract
Petit T, Cavelier-Balloy B, Vilmer C, Rivet J, et al.
Annales de dermatologie et de venereologie · 1984 · English Abstract
Vilmer C, Pérol Y
The Journal of investigative dermatology · 2006 · Journal Article
Liboutet M, Portela M, Delestaing G, Vilmer C, et al.
Acta dermato-venereologica · 2018 · Journal Article
Lhote R, Lambert J, Lejeune J, Gottlieb J, et al.
Acta dermato-venereologica · 2018 · Journal Article
Lhote R, Lambert J, Lejeune J, Gottlieb J, et al.